Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q2 revenue increased 10.2% to $3.04 billion, adjusted EPS beat expectations at $3.12, and 2026 revenue guidance was raised. The stock gained 7% over 21 sessions and closed at a period and 52-week high.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Expansion ⢠Liquidity Improvement ⢠Leverage Risk DGX offers improving margins, strong cash flow, and enhanced liquidity, but elevated debt, intangible-heavy assets, and premium valuation temper upside.
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Resistance Testing ⢠Mild Downtrend Support Level: $234â$236 Resistance Level: $240â$241 DGX is mildly bearish over the last month, holding $234â$236 support but needing a break above $241 to target $244â$245.
Sentiment & News
Key News Insights: ⢠Analyst upgrades ⢠Diagnostic expansion ⢠Institutional buying Quest Diagnostics' strong stock momentum, analyst support, institutional buying, and expanded diagnostics offerings signal positive growth potential despite debt and reimbursement risks.
AI Summary
Quest's specialty-diagnostics expansion could lift pricing power and margins through its existing network, but with DGX near highs and valued for continued execution, investors should wait for quantified reimbursement, adoption, and profit contribution from MRD, Alzheimer's, and kidney testing before adding aggressively.
Description
Quest Diagnostics is a provider of diagnostic testing and related information services in the U.S. and internationally, offering a spectrum of laboratory testing from routine to advanced clinical and anatomic pathology under multiple brands. Its customers include patients, clinicians, hospitals, health plans, employers and life insurers, and it delivers services through laboratories, patient service centers, physician-office phlebotomists, mobile clinicians and call centers. The company also supplies life-insurance risk assessment services and health care IT solutions and is headquartered in Secaucus, New Jersey, where it was founded in 1967.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 21 | Aug 28 | DGX | Quest Diagnostics Incorporated | Q2 revenue increased 10.2% to $3.04 billion, adjusted EPS beat expectations at $3.12, and 2026 revenue guidance was raised. The stock gained 7% over 21 sessions and closed at a period and 52-week high. | Closed | -0.7% |
| Feb 27 | Mar 6 | DGX | Quest Diagnostics Incorporated | Quest Diagnostics rallied ~28.5% over 21 days on a Q4/FY2025 beat, above-Street FY2026 guidance, a $1B buyback expansion and 7.5% dividend hike; strong FCF and advanced diagnostics launches (Haystack MRD, CoLab expansion) support near-term continuation from pullbacks toward the 190â205 support band. | Closed | -6.0% |